← Back to screener

FENNEC PHARMACEUTICALS INC. FENC

Rank #2083 · Nasdaq · $0.4B market cap
Audited by HASKELL & WHITE LLP, no going-concern flag in the latest filing.
Score
34.5
P/E
-815.8
P/B
-30.61
ROE
3.8%
Op. Margin
5.4%
Debt Ratio
-437%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -815.8x, P/B -30.61x. Ranks in the top 82% of the universe.

Profitability ★★☆☆☆
Weak

ROE 3.8%. Ranks in the top 60% of the universe.

Safety ★★★★★
Excellent

Debt ratio -437%. Ranks in the top 4% of the universe. Under 100% is generally considered a safe level.

Growth ★★★★★
Excellent

Revenue growth of 123.7% year over year. Ranks in the top 3% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011–$-0.0B$-0.0B$-0.0B–-29505
2012$0.0B$-0.0B$-0.0B$0.0B––
2013$0.0B$-0.0B$-0.0B$0.0B––
2014$0.0B$-0.0B$0.0B$-0.0B–-65
2015$0.0B$-0.0B$-0.0B$-0.0B–-121
2016$0.0B$-0.0B$-0.0B$0.0B–77
2017$0.0B$-0.0B$-0.0B$0.0B–73
2018$0.0B$-0.0B$-0.0B$0.0B–46
2019$0.0B$-0.0B$-0.0B$0.0B–6
2020–$-0.0B$-0.0B$0.0B–11
2021$0.0B$-0.0B$-0.0B$0.0B-10520.620
2022–$-0.0B$-0.0B$0.0B–23
2023$0.0B$-0.0B$-0.0B$0.0B-1471.6187
2024$0.0B$-0.0B$-0.0B$-0.0B-60.1-1498
2025$0.0B$0.0B$-0.0B$-0.0B5.4-437

← See the full screener